Outcomes and Treatment Patterns of Adding a Third Agent to 2 OADs in Patients with Type 2 Diabetes

BACKGROUND: Patients with uncontrolled type 2 diabetes mellitus (T2DM), despite therapy with 2 oral antidiabetic drugs (OADs), may add a third OAD or a glucagon-like peptide-1 receptor agonist (GLP-1) or initiate insulin therapy. The transition to insulin has been shown to be delayed in current prac...

Descripción completa

Detalles Bibliográficos
Autores principales: Levin, Philip A., Wei, Wenhui, Zhou, Steve, Xie, Lin, Baser, Onur
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438237/
https://www.ncbi.nlm.nih.gov/pubmed/24761822
http://dx.doi.org/10.18553/jmcp.2014.20.5.501

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438237/
https://www.ncbi.nlm.nih.gov/pubmed/24761822
http://dx.doi.org/10.18553/jmcp.2014.20.5.501

Ejemplares similares